Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Persistent Asthma (Asia-Pacific)
NCT03782532Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2019
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of dupilumab in asthma, sponsored by Sanofi. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03782532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782532.